Back to Authors

Walsh, Patrick C.

Mayo Clinic

Mayo Clinic

Citations 3

VALIDATION OF PARTIN TABLES FOR PREDICTING PATHOLOGICAL STAGE OF CLINICALLY LOCALIZED PROSTATE CANCER
Blute, Michael L., Bergstralh, Erik J., Partin, Alan W. , Walsh, Patrick C., Kattan, Michael W. , Scardino, Peter T. , Montie, James E. , Pearson, Jay D., Slezak, Jeffrey M., Zincke, Horst, Kattan, Michael W

Journal of Urology | January 18, 2006 | Volume: 164 | Issue: 5 | Pages: 1591-1595

10.1016/s0022-5347(05)67035-8 Get It

Standard Versus Age-Specific Prostate Specific Antigen Reference Ranges Among Men With Clinically Localized Prostate Cancer: A Pathological Analysis
Partin, Alan W. , Criley, Stuart R. , Subong, Eric N.P., Zincke, Horst, Walsh, Patrick C., Oesterling, Joseph E.

Journal of Urology | January 17, 2006 | Volume: 155 | Issue: 4 | Pages: 1336-1339

10.1016/s0022-5347(01)66260-8 Get It

A Germline DNA Polymorphism Enhances Alternative Splicing of the KLF6 Tumor Suppressor Gene and Is Associated with Increased Prostate Cancer Risk
Narla, Goutham , DiFeo, Analisa , Reeves, Helen L. , Schaid, Daniel J. , Hirshfeld, Jennifer, Hod, Eldad A. , Katz, Amanda, Isaacs, William B., Hebbring, Scott J. , Komiya, Akira , McDonnell, Shannon K. , Wiley, Kathleen E. , Jacobsen, Steven J. , Isaacs, Sarah D., Walsh, Patrick C., Chang, Bao-Li, Friedrichsen, Danielle M., Stanford, Janet L. , Ostrander, Elaine A. , Chinnaiyan, Arul M., Rubin, Mark A. , Xu, Jianfeng , Thibodeau, Stephen N. , Martignetti, John A., Karyadi, Danielle M. , Zheng, Shusen , Chang, Bao‐Li, Friedman, Scott L. , DiFeo, Analisa , Rubin, Mark A , McDonnell, Shannon K

Cancer Research | September 15, 2005 | Volume: 65 | Issue: 4 | Pages: 1213-1222

10.1158/0008-5472.can-04-4249 Get It

Abstract Prostate cancer is a leading and increasingly prevalent cause of cancer death in men. Whereas family history of disease is one of the strongest prostate cancer risk factors and suggests a hereditary component, the predisposing genetic factors remain unknown. We first showed that KLF6 is a tumor suppressor somatically inactivated in prostate cancer and since then, its functional loss has been further established in prostate cancer cell lines and other human cancers. Wild-type KLF6, but not patient-derived mutants, suppresses cell growth through p53-independent transactivation of p21. Here we show that a germline KLF6 single nucleotide polymorphism, confirmed in a tri-institutional study of 3,411 men, is significantly associated with an increased relative risk of prostate cancer in men, regardless of family history of disease. This prostate cancer–associated allele generates a novel functional SRp40 DNA binding site and increases transcription of three alternatively spliced KLF6 isoforms. The KLF6 variant proteins KLF6-SV1 and KLF6-SV2 are mislocalized to the cytoplasm, antagonize wtKLF6 function, leading to decreased p21 expression and increased cell growth, and are up-regulated in tumor versus normal prostatic tissue. Thus, these results are the first to identify a novel mechanism of self-encoded tumor suppressor gene inactivation and link a relatively common single nucleotide polymorphism to both regulation of alternative splicing and an increased risk in a major human cancer.